FY2027 EPS Forecast for Gilead Sciences Boosted by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Analysts at Erste Group Bank raised their FY2027 earnings estimates for Gilead Sciences in a research report issued on Friday, September 18th. Erste Group Bank analyst H. Engel now expects that the biopharmaceutical company will post earnings per share of $9.88 for the year, up from their prior forecast of $9.86. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.48) per share.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $7.80 billion during the quarter, compared to analysts’ expectations of $7.40 billion. During the same period in the previous year, the company earned $2.01 earnings per share. Gilead Sciences’s revenue for the quarter was up 10.6% on a year-over-year basis.

A number of other research firms have also recently issued reports on GILD. Barclays decreased their price target on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a report on Wednesday, July 29th. Morgan Stanley dropped their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a research note on Monday, July 27th. Needham & Company LLC reissued a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Wednesday, August 5th. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Finally, Truist Financial lowered their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $158.78.

Gilead Sciences Stock Performance

Shares of GILD opened at $152.67 on Monday. The company has a market capitalization of $189.30 billion, a PE ratio of -57.18 and a beta of 0.33. Gilead Sciences has a one year low of $108.46 and a one year high of $157.29. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The company’s fifty day moving average price is $140.82 and its 200 day moving average price is $136.27.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. Gilead Sciences’s payout ratio is currently -122.85%.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the transaction, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the firm’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $145.29, for a total value of $435,870.00. Following the completion of the transaction, the chief financial officer directly owned 164,096 shares of the company’s stock, valued at approximately $23,841,507.84. This trade represents a 1.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock valued at $14,616,390 in the last quarter. 0.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Gilead Sciences

Several institutional investors have recently made changes to their positions in GILD. Persistent Asset Partners Ltd bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at $25,000. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the fourth quarter worth about $25,000. Kimelman & Baird LLC bought a new position in Gilead Sciences during the second quarter worth about $25,000. Wealth Preservation Advisors LLC grew its stake in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares during the period. Finally, Wilkerson Advisory Group LLC grew its stake in Gilead Sciences by 54.2% in the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 78 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Erste Group modestly raised its FY2026 EPS forecast for Gilead to a loss of $0.44 per share from a prior estimate of a $0.45 loss. The revised forecast is also better than the broader consensus estimate of a $0.48 loss, providing a small positive signal for earnings expectations. Gilead Sciences FY2027 EPS Raised by Erste Group Bank
• Positive Sentiment: A stock-picking analysis identified Gilead as a cash-producing company worth considering, which may support the investment case for its relatively defensive business and cash-flow profile. The article also cautions that strong cash generation does not automatically lead to attractive returns if capital is poorly allocated. 1 Cash-Producing Stock on Our Buy List and 2 We Find Risky
• Neutral Sentiment: Recent market reports showed GILD finishing around $152.67, with one report describing a 1.4% gain and another citing a 0.7% decline at the close. The conflicting descriptions suggest normal trading volatility rather than a clearly identified company-specific catalyst. Gilead Sciences Stock Moves
• Neutral Sentiment: Comparisons with Bristol Myers Squibb and Protalix BioTherapeutics provide valuation and pipeline context, but do not announce a new development for Gilead. BMY vs GILD
• Negative Sentiment: One report highlighted a 0.7% pullback at the close, underscoring some short-term selling pressure after GILD’s recent advance. However, no fundamental reason for the decline was provided. Gilead Sciences Stock Slips

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.